Volume 25

19

A case of hemolytic uremic syndrome improved with nitric oxide

Year:
2000
Language:
english
File:
PDF, 40 KB
english, 2000
33

Busulfan clearance in renal failure and hemodialysis

Year:
2000
Language:
english
File:
PDF, 51 KB
english, 2000
48

Establishing a BMT support group

Year:
2000
Language:
english
File:
PDF, 42 KB
english, 2000
76

Response to Dr Furebring

Year:
2000
Language:
english
File:
PDF, 30 KB
english, 2000
92

Editor's Note

Year:
2000
Language:
english
File:
PDF, 20 KB
english, 2000
98

Criteria for assessing chronic GVHD

Year:
2000
Language:
english
File:
PDF, 23 KB
english, 2000
113

Randomised studies in acute myeloid leukaemia: the double truth

Year:
2000
Language:
english
File:
PDF, 32 KB
english, 2000
114

Dr Frassoni’s paper was shown to Dr Sue Richards, who has commented as follows

Year:
2000
Language:
english
File:
PDF, 29 KB
english, 2000
118

Mini-allografts: ongoing trials in humans

Year:
2000
Language:
english
File:
PDF, 66 KB
english, 2000
131

An overview of the Welsh Bone Marrow Donor Registry: 10 years of bone marrow donor provision

Year:
2000
Language:
english
File:
PDF, 90 KB
english, 2000
137

Cross-sensitivity reaction between tacrolimus and macrolide antibiotics

Year:
2000
Language:
english
File:
PDF, 27 KB
english, 2000
153

Errata

Year:
2000
File:
PDF, 14 KB
2000
158

Van Bekkum Award

Year:
2000
File:
PDF, 36 KB
2000
159

Presidential Symposium

Year:
2000
File:
PDF, 269 KB
2000
160

Acute leukaemias

Year:
2000
File:
PDF, 251 KB
2000
161

Chronic leukaemia I

Year:
2000
File:
PDF, 203 KB
2000
162

Chronic leukaemia II

Year:
2000
File:
PDF, 209 KB
2000
163

Alternative stem cell sources

Year:
2000
File:
PDF, 179 KB
2000
164

Umbilical cord transplant

Year:
2000
File:
PDF, 204 KB
2000
165

Aplastic anaemia

Year:
2000
File:
PDF, 96 KB
2000
166

Ovarian and breast cancer

Year:
2000
File:
PDF, 152 KB
2000
167

Cell therapy

Year:
2000
File:
PDF, 262 KB
2000
168

Allogeneic transplants with reduced conditioning I

Year:
2000
File:
PDF, 200 KB
2000
169

Allogeneic transplants with reduced conditioning II

Year:
2000
File:
PDF, 184 KB
2000
170

Allogeneic transplants: Harvest and outcome

Year:
2000
File:
PDF, 200 KB
2000
171

Conditioning regimens

Year:
2000
File:
PDF, 195 KB
2000
172

Graft versus host disease I

Year:
2000
File:
PDF, 214 KB
2000
173

Graft versus host disease II

Year:
2000
File:
PDF, 196 KB
2000
174

Lymphoma

Year:
2000
File:
PDF, 262 KB
2000
175

Inborn errors

Year:
2000
File:
PDF, 132 KB
2000
176

Infectious diseases I

Year:
2000
File:
PDF, 271 KB
2000
177

Infectious diseases II

Year:
2000
File:
PDF, 203 KB
2000
178

Late effects

Year:
2000
File:
PDF, 174 KB
2000
179

Multiple myeloma

Year:
2000
File:
PDF, 238 KB
2000
180

Minimal residual disease

Year:
2000
File:
PDF, 210 KB
2000
181

Myelodysplasia

Year:
2000
File:
PDF, 207 KB
2000
182

Paediatrics I

Year:
2000
File:
PDF, 220 KB
2000
183

Paediatrics II

Year:
2000
File:
PDF, 177 KB
2000
184

Paediatrics III

Year:
2000
File:
PDF, 142 KB
2000
185

Solid tumours – Auto‐ and allogeneic

Year:
2000
File:
PDF, 139 KB
2000
186

Solid tumours – Miscellaneous

Year:
2000
File:
PDF, 185 KB
2000
187

TRM after stem cell transplantation

Year:
2000
File:
PDF, 177 KB
2000
188

Stem cell/Engraftment/Reconstitution

Year:
2000
File:
PDF, 246 KB
2000
189

Psychooncology

Year:
2000
File:
PDF, 136 KB
2000
190

Autoimmune diseases

Year:
2000
File:
PDF, 118 KB
2000
201

CD34 selected alloPBSCT and adoptive immunotherapy

Year:
2000
Language:
english
File:
PDF, 53 KB
english, 2000
204

New strategies in the treatment of graft-versus-host disease

Year:
2000
Language:
english
File:
PDF, 44 KB
english, 2000
205

New strategies in GVHD prophylaxis

Year:
2000
Language:
english
File:
PDF, 48 KB
english, 2000
207

Autologous and allogeneic stem cell transplantation in multiple myeloma

Year:
2000
Language:
english
File:
PDF, 43 KB
english, 2000
212

Targeting p53, hdm2, and CD19: vaccination and immunologic strategies

Year:
2000
Language:
english
File:
PDF, 38 KB
english, 2000
214

Treatment of patients with malignant lymphomas with monoclonal antibodies

Year:
2000
Language:
english
File:
PDF, 50 KB
english, 2000
220

Development of a cytomegalovirus vector for somatic gene therapy

Year:
2000
Language:
english
File:
PDF, 50 KB
english, 2000
225

Engineering drug resistance in human cells

Year:
2000
Language:
english
File:
PDF, 60 KB
english, 2000
246

High-dose therapy in breast cancer: out of favor but not out of promise

Year:
2000
Language:
english
File:
PDF, 40 KB
english, 2000
248

Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT

Year:
2000
Language:
english
File:
PDF, 34 KB
english, 2000
251

Posters P1–P21

Year:
2000
File:
PDF, 616 KB
2000
269

Can science and politics really be divorced?

Year:
2000
Language:
english
File:
PDF, 64 KB
english, 2000
280

Results of allogeneic BMT in 16 patients with Fanconi’s anemia

Year:
2000
Language:
english
File:
PDF, 39 KB
english, 2000
289

Preface

Year:
2000
Language:
english
File:
PDF, 14 KB
english, 2000
290

Index

Year:
2000
File:
PDF, 17 KB
2000
291

Sponsors

Year:
2000
File:
PDF, 13 KB
2000
294

Response

Year:
2000
Language:
english
File:
PDF, 22 KB
english, 2000
297

Bone marrow transplantation does not correct the hyper IgE syndrome

Year:
2000
Language:
english
File:
PDF, 41 KB
english, 2000
304

Author index to Volume 25

Year:
2000
File:
PDF, 55 KB
2000
305

Keyword index to Volume 25

Year:
2000
Language:
english
File:
PDF, 37 KB
english, 2000
306

Response

Year:
2000
Language:
english
File:
PDF, 39 KB
english, 2000
307

GVHD dry eyes treated with autologous serum tears

Year:
2000
Language:
english
File:
PDF, 237 KB
english, 2000
309

Graft versus host disease

Year:
2000
File:
PDF, 1023 KB
2000
310

Breast cancer

Year:
2000
File:
PDF, 438 KB
2000
311

Hodgkin's disease

Year:
2000
File:
PDF, 1014 KB
2000
312

Protective care/management issues

Year:
2000
File:
PDF, 145 KB
2000
313

Cytokine

Year:
2000
File:
PDF, 1.05 MB
2000
314

Late effects

Year:
2000
File:
PDF, 1.14 MB
2000
315

Mechanism of tolerance, rejection

Year:
2000
File:
PDF, 192 KB
2000
316

Minimal residual disease

Year:
2000
File:
PDF, 1.12 MB
2000
317

Paediatric diseases

Year:
2000
File:
PDF, 350 KB
2000
318

Miscellaneous

Year:
2000
File:
PDF, 2.17 MB
2000
319

Complementary therapies/palliative care/ethical issues

Year:
2000
File:
PDF, 191 KB
2000
320

Outpatient care

Year:
2000
File:
PDF, 221 KB
2000
321

Psychosocial issues/workshop/poster session

Year:
2000
File:
PDF, 317 KB
2000
322

Paediatric session

Year:
2000
File:
PDF, 283 KB
2000
323

Donor issues/collaboration across europe

Year:
2000
File:
PDF, 318 KB
2000
324

Late abstracts

Year:
2000
File:
PDF, 222 KB
2000
325

Cytokine

Year:
2000
File:
PDF, 1.05 MB
2000
326

Late effects

Year:
2000
File:
PDF, 1.14 MB
2000
327

Mechanism of tolerance, rejection

Year:
2000
File:
PDF, 192 KB
2000
328

Minimal residual disease

Year:
2000
File:
PDF, 1.12 MB
2000
329

Paediatric diseases

Year:
2000
File:
PDF, 350 KB
2000
330

Miscellaneous

Year:
2000
File:
PDF, 2.17 MB
2000
331

Complementary therapies/palliative care/ethical issues

Year:
2000
File:
PDF, 191 KB
2000
332

Outpatient care

Year:
2000
File:
PDF, 221 KB
2000
333

Psychosocial issues/workshop/poster session

Year:
2000
File:
PDF, 317 KB
2000
334

Paediatric session

Year:
2000
File:
PDF, 283 KB
2000
335

Donor issues/collaboration across europe

Year:
2000
File:
PDF, 318 KB
2000
336

Late abstracts

Year:
2000
File:
PDF, 222 KB
2000